Company Update: CVS Caremark Corporation (NYSE:CVS) – CVS urges cost controls for new cholesterol drugs

[Reuters] – Two of the new injectable cholesterol treatments, called PCSK9 inhibitors, could gain U.S. approval this summer. CVS said they could eventually be used by as many as 15 million patients at . . . → Read More: Company Update: CVS Caremark Corporation (NYSE:CVS) – CVS urges cost controls for new cholesterol drugs Similar Articles: Market Update: CVS Caremark Corporation (NYSE:CVS) – CVS Health To Present At RBC Capital Markets Healthcare Conference Company Update (NYSE:UNH): UnitedHealth CEO predicts growth across the company in 2015 Company Update (NYSE:UNH): UnitedHealth to buy doctor management company MedSynergies